The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients.
Clinical effects, levels of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) and lithium levels in serum were examined in 13 manic depressive patients acutely admitted because of a manic or hypomanic episode. Patients were examined before and 12 days after the beginning of lithium treatment. Manic scores were significantly reduced during treatment. The levels of 5-HIAA as well as HVA increased significantly during treatment. The HVA to 5-HIAA ratio was significantly reduced, indicating a more pronounced change in 5-HIAA than in HVA. The 5-HIAA and HVA levels before as well as after 12 days of treatment were significantly correlated. No significant correlation was found between manic scores and monoamine metabolites in CSF or between lithium level in serum and reduction of manic scores or elevation of monoamine metabolites in CSF in the relative small number of patients studied.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008094:Lithium / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D011569:Psychiatric Status Rating Scales
D010648:Phenylacetates; D006897:Hydroxyindoleacetic Acid; D008094:Lithium; D006719:Homovanillic Acid